Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS's Zeposia Shines in Ulcerative Colitis Phase III Study

Success Augurs Well For S1P Drug Class in UC

Executive Summary

BMS’s S1P receptor modulator met endpoints in a Phase III trial treating patients with moderate to severe ulcerative colitis, boosting the drug class’s prospects in that condition.

You may also be interested in...



Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.

BMS Has A Lot Of Ground To Make Up Ahead Of Patent Expiries

Bristol Myers Squibb is struggling to restore Opdivo’s growth and COVID-19 sales impacts didn’t help in Q1. New indications are coming but new products, like Zeposia, are slow to add significant revenue.

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel